RZLT
Rezolute, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.84
−2.78%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.91
From 52W high−64.90%
Volume2.52M
Market cap$369.76M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$3.91
From 52W high
−64.90%
Volume
2.52M
Market cap
$369.76M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.1x
P/E (TTM)
—
RSI (14)
28.1
MomentumView details →
1D Return
−2.78%
YTD Return
+57.51%
SummaryUpdated Mar 1, 2026
Rezolute, Inc. (NASDAQ:RZLT) is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Redwood City, California. Originally incorporated as AntriaBio, Inc., the company rebranded to Rezolute in December 2017 to better reflect its focus on developing transformative therapies for metabolic diseases. The company went public in January 2013 and has since dedicated its efforts to addressing rare and complex conditions associated with chronic glucose imbalance, particularly targeting ultra-rare pediatric genetic disorders and diabetic complications.
Similar companies
Latest newsMore news →
Bank of America Corp DE reduced its stake in Rezolute, Inc. by 31.3% during the quarter, selling 1,354,699 shares, according to its Form 13F filing.26d agoRezolute, Inc. reported an interim update from its ongoing Phase 3 upLIFT study evaluating ersodetug in patients with tumor hyperinsulinism.110d ago